A phase II trial of high‐dose intravenous interferon alpha‐2 in advanced colorectal cancer

Twenty‐one patients with metastatic colorectal cancer were treated with high‐dose intravenous interferon alpha‐2 (30–50 × 106 units/m2) administered daily for 5 consecutive days. Courses of therapy were repeated every 2 to 3 weeks. No tumor responses were seen among 15 evaluable patients. In two sub...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 54; no. 10; pp. 2257 - 2261
Main Authors Silgals, Robert M., Ahlgren, James D., Neefe, John R., Rothman, John, Rudnick, Seth, Galicky, F. Peter, Schein, Philip S.
Format Journal Article Conference Proceeding
LanguageEnglish
Published New York Wiley Subscription Services, Inc., A Wiley Company 15.11.1984
Wiley-Liss
Subjects
Adult
Aged
Biological and medical sciences
Chemical and Drug Induced Liver Injury
Colonic Neoplasms - therapy
Dose-Response Relationship, Drug
Drug Evaluation
Fatigue - chemically induced
Female
Fever - chemically induced
Humans
Immunomodulators
Infusions, Parenteral
Interferon Type I - administration & dosage
Interferon Type I - adverse effects
Interferon Type I - therapeutic use
Leukopenia - chemically induced
Liver Diseases - enzymology
Male
Medical sciences
Middle Aged
Nausea - chemically induced
Neoplasm Metastasis
Pharmacology. Drug treatments
Rectal Neoplasms - therapy
Antineoplastic agent
Human
Intravenous administration
Alpha interferon
Treatment
Immunotherapy
Phase II trial
Rectum
Digestive diseases
Intestinal disease
Advanced stage
Tumor
Colon
High dose
Online AccessGet full text
ISSN0008-543X
1097-0142
DOI10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C

Cover

More Information
Summary:Twenty‐one patients with metastatic colorectal cancer were treated with high‐dose intravenous interferon alpha‐2 (30–50 × 106 units/m2) administered daily for 5 consecutive days. Courses of therapy were repeated every 2 to 3 weeks. No tumor responses were seen among 15 evaluable patients. In two subjects, disease remained stable for 3 and 7 months, respectively. Toxicity was substantial and a de‐escalation of dose was frequently required. Fevers, gastrointestinal symptoms, fatigue, leukopenia, and elevated serum transaminases were common. High‐dose interferon was found to be ineffective in the treatment of metastatic colorectal cancer. A daily dose of 50 × 106 units/m2 was greater than the maximum tolerated dose in this group of patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C